Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy. Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL. To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002. All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients. The estimated 3-year overall and relapse-free survival, and disease relapse were 45.3, 33.8 and 39.3%, respectively. Among 10 cases with ATLL relapse, five cases achieved CR again: three by the reduction or cessation of immunosuppressive agents, which suggested a graft-versus-ATLL (GvATLL) effect. However, univariate or multivariate analysis did not show any benefit of graft-versus-host disease (GVHD) on the prevention of relapse. These results suggested that allo-HSCT was effective for some patients with aggressive ATLL, and that the GvATLL effect could be achieved even without GVHD. A new phase II trial to test the efficacy of allo-HSCT for ATLL is warranted.
Introduction
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell neoplasm associated with the infection of a specific retrovirus, human T-cell lymphotropic virus type-I (HTLV-I). [1] [2] [3] [4] ATLL is quite different from other types of non-Hodgkin's lymphoma (NHL): restricted endemic areas including the west coast of Japan, with distinct clinical features such as high frequency of hypercalcemia, a strong predisposition to infection and poor response to chemotherapy. 4, 5 Multicenter clinical trials for ATLL conducted by the Japan Clinical Oncology Group (JCOG) have shown that standard-dose chemotherapy for NHL was unable to cure any patients with acute or lymphoma types of ATLL, which is more aggressive than the chronic or smoldering type. [5] [6] [7] The best chemotherapy result for those patients was obtained from the phase II trial of a new multidrug regimen containing nine agents with the support of granulocyte colony-stimulating factor (JCOG9303, LSG15 protocol). 8 The overall survival (OS) rate of the 93 patients in this trial was estimated at 31% at 2 years. In these circumstances, high-dose chemotherapy/radiotherapy with hematopoietic stem cell transplantation (HSCT) was applied to those patients, particularly in Japan. The results of allogeneic, not autologous, HSCT reported by several groups, including ours, suggested that it could provide durable clinical responses for some patients with ATLL. [9] [10] [11] [12] [13] [14] However, the number of patients in each report was so small that the efficacy of allogeneic HSCT (allo-HSCT) for ATLL is still controversial. In this report, we aimed to extend our previous study to establish the basis for a phase II clinical trial of allo-HSCT for aggressive ATLL by retrospectively collecting a larger number (40) of transplants from seven institutions in Japan. Our results suggested that allo-HSCT is effective for some patients with ATLL, and that there may be a graft-versus-ATLL (GvATLL) effect that cannot be obtained by chemotherapy alone or high-dose therapy with autograft.
Patients and methods

Study design, data collection and transplantation procedure
This is a retrospective analysis of myeloablative allo-HSCT for patients with ATLL performed at seven institutions in Japan from June 1997 to April 2002. Data on donors and recipients were collected using questionnaires distributed to each participating center in this study. Patients included in this study received intensive conditioning regimens prior to stem cell transplantation. The early results of the four out of 40 cases were reported previously. 14 Since transplantation was performed following the protocol of each institution, the conditioning regimen or prophylaxis for GVHD varied among institutions (Table 1) ; however, all but one preconditioning regimens had myeloablative intensity (containing more than 12 Gy of total body irradiation (TBI, 22 cases), 16 mg/kg of busulfan (17 cases) and 140 mg/m 2 of melphalan (one case)).
Definitions of clinical end points and responses
The day of engraftment was defined as the first of 3 consecutive days on which the neutrophil count exceeded 0.5 Â 10 9 /l.
Patients who died before day 28 were considered unevaluable for engraftment. Relapse-free survival (RFS) was defined as the time interval from transplantation to the first event (either relapse or death in complete remission (CR)). Acute graft-versushost disease (aGVHD) was diagnosed and graded at each transplantation center according to the standard criteria with grades 0, I, II, III and IV. 15 Chronic GVHD (cGVHD) was defined according to standard criteria of absent, limited or extensive. 16 One patient, who received transplantation at the stage of progressive disease (PD), died of infection on day 8 after transplantation, and this case was excluded from the analysis of engraftment, response to transplantation and GVHD. The response criteria used in this report followed those established by JCOG. 8 CR was defined as the disappearance of all clinical and radiographic evidence of disease and the normalization of lactate dehydrogenase (LDH). As HTLV-I carriers frequently have a small percentage of abnormal lymphocytes, CR was judged with less than 5% of such cells if the absolute lymphocyte count was less than 4 Â 10 9 /l. Partial response (PR) was defined as a X50% reduction of the measurable disease with more than 75% reduction in the absolute abnormal lymphocyte count. LDH had to be decreased to o1.5 of the normal upper limit. PD was defined by X25% increase of the measurable disease or the appearance of new lesions while under treatment. No change (NC) was defined by an intermediate response between PR and PD.
Statistical analysis
The Kaplan-Meier method was used to estimate OS and RFS. The 95% confidence intervals of 3-year OS and RFS were calculated. For analyzing the relapse after transplantation, the cumulative distribution function of relapse was calculated. The differences in the OS and RFS rates between the groups of transplantation-related factors were compared by the log-rank test. Among those who reached CR after transplantation, the differences in the proportion of ATLL relapse between the groups of transplantation-related factors were compared by the w 2 test. Furthermore, simultaneous effects of prognostic factors on survival (OS and RFS) and relapse were analyzed using multivariate regression analysis based on the Cox's proportional hazards model and the linear logistic model, respectively. The most appropriate models were selected based on Akaike's information criteria (AIC). All analyses were performed using SAS (Statistical Analysis System Inc., Cary, NC, USA) software.
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Results
Patient characteristics and transplant conditions
Data on 40 transplantations were collected. The clinical characteristics of patients are summarized in Table 1 . All patients received standard-dose chemotherapy before the procedure of transplantation, and 28 patients (70%) showed a clinical response to the previous chemotherapy. Nine related donors showed a positive result for the anti-HTLV-I antibody.
The peripheral blood mononuclear cells of these donors were subjected to Southern blot analysis to examine the monoclonal integration of HTLV-I provirus into the genome, and all nine donors were confirmed as carriers of HTLV-I.
Engraftment and response to transplantation
The median number of cells transplanted was 3. GVHD and transplantation-related early toxicity aGVHD developed in 26 of 39 patients (66.7%), and 15 out of 31 patients developed cGVHD (Table 2 ). There were 21 deaths after transplantation, and 16 were related to adverse events of transplantation (Table 2) . Within 6 months after transplantation, 15 patients died: 13 were lost to adverse events of transplantation. Sustained long-term survival of patients with ATLL after allo-HSCT T Fukushima et al
Survival and relapse of ATLL
The median survival time of all cases after transplantation was 9.6 months (range 0.3-63.6 months), and the median observation time of 19 surviving patients was 22.7 months (3.7-63.6) ( Table 2 and Figure 1 ). Estimated OS and RFS rates at 3 years were 45.3% (95% confidence interval (CI): 31.8-58.8%) and 33.8% (95% CI: 17.2-49.4%), respectively (Figures 1 and 2 ). ATLL relapse occurred in 10 patients after transplantation ( Table 2 ). The estimated risk of disease relapse at 3 years was 39.3% (95% CI: 19.7-58.9%) (Figure 3 ). However, five achieved another CR: three by reduction or cessation of immunosuppressive agents, one by standard-dose chemotherapy and one by local radiation therapy. Among these five patients, three maintained CR over 1 year.
Univariate and multivariate analysis for survival and relapse
The univariate analysis for survival identified several pretransplantation and posttransplantation factors ( Table 3 ). The performance status before transplantation had a significant impact on OS and RFS, but the disease status at transplantation did not. The existence of aGVHD or cGVHD did not affect the ATLL relapse, and aGVHD (grades I-IV) had a significant negative impact on OS and RFS. Patients with grade 0 or I aGVHD showed no significant difference on their OS or RFS from those with stronger aGVHD. Transplantation from a carrier donor was associated with better survival than from an HTLV-Inegative donor. Multivariate analysis selected several factors for survival and relapse (Table 4) . Among factors selected, the presence of aGVHD had a significant negative impact on both OS and RFS. For RFS, transplant from related donor showed better results. Transplantation from a carrier donor had RFS after transplantation. The estimated 3-year RFS rate was 33.8%.
Figure 3
Cumulative distribution function of relapse after transplantation.
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Discussion
This retrospective study reported the outcome of allo-HSCT for 40 patients with ATLL who received intensive treatment (myeloablative intensity in most cases) as a conditioning regimen before transplantation. The OS and RFS rates at 3 years were 45.3 and 33.8%, respectively, and these results were comparable with our previous report of 10 cases.
14 Patients in this study were diagnosed with either the acute or lymphoma type of ATLL, which usually shows an aggressive clinical course. 7 Among 11 evaluable patients who received transplantation at the point of resistant disease (NC and PD), all but one Sustained long-term survival of patients with ATLL after allo-HSCT T Fukushima et al patient achieved CR after transplantation, suggesting the efficacy of myeloablative conditioning to ATLL. In this analysis, there was no difference in the incidence of relapse or survival among patients treated with busulfan-based regimens and TBI-containing regimens. It seemed that chemotherapy was as effective as TBI for ATLL in terms of a conditioning regimen for allo-HSCT. The major difference between autologous and allo-HSCT was the incidence of relapse of the primary disease after transplantation. We reported previously that relapse occurred in all four evaluable cases after autologous HSCT. 9 In contrast, 10 out of 39 cases (25.6%) suffered ATLL relapse after allo-HSCT. The immunological reaction induced only by allo-HSCT could control the residual ATLL after high-dose therapy, which may be called the GvATLL effect. In this study, among 10 patients in whom ATLL relapsed after transplantation, five patients achieved second CR. Interestingly, three achieved CR only by the reduction or cessation of immunosuppressive agents. This observation further supported the idea that the GvATLL effect actually worked and contributed to long-term RFS. One of the clinical findings supporting the idea of graft-versus-leukemia (or lymphoma) effect is the benefit of GVHD in the prevention of disease relapse, [18] [19] [20] for example, as shown in NHL in which grades II-IV aGVHD were associated with a lower incidence of disease progression after transplantation from an unrelated donor. 21 In this study, however, we found no positive effect of GVHD on freedom from relapse, or long-term survival by univariate and multivariate analysis. On the other hand, the existence of aGVHD, even grade I, negatively affected the OS and RFS. Of note, the negative impact of GVHD on the survival did not change by the analysis with Cox's proportional hazard model (in the analysis of aGVHD1, P ¼ 0.06 for OS and P ¼ 0.02 for RFS), which treats GVHD as a time-dependent covariate, although nine cases lacking some clinical data were missed in this analysis. The possible GvATLL effect (second CR obtained by the reduction or cessation of immunosuppressive agents) but no benefit of aGVHD and cGVHD on the survival or the prevention of relapse (demonstrated by the univariate and multivariate analysis) suggests that the GvATLL effect could work on those patients even without clinically obvious GVHD. This hypothesis is in concordance with our recent observation 22 that showed the development of cytotoxic T cells specific for Tax, one of the HTLV-I products, in patients after nonmyeloablative allo-HSCT for ATLL. In some patients, the HTLV-Iinfected cell-specific immune reaction may contribute to the eradication of ATLL.
A total of 21 patients died after allo-HSCT, and 15 of those 21 patients were lost within 6 months after HSCT mostly due to treatment-related adverse events. We assume that both intensive conditioning before transplantation and the immunological reaction between graft and host after transplantation were effective for ATLL; however, these two factors also had a negative impact on the survival of patients at the same time. As shown in the univariate analysis, the general status of patients but not the disease status at transplantation was significantly related with the survival after transplantation. The indication of myeloablative allo-HSCT for ATLL needs to be determined based on the general status rather than disease status to reduce TRM. Furthermore, because patients with ATLL are immunocompromised, 4,7 the strengthening of supportive care for infection and the development of less toxic conditioning could contribute to a better outcome. In this respect, nonmyeloablative conditioning will also be tested for ATLL. As shown by multivariate analysis, it seems important to control aGVHD for patients with ATLL. Transplantation from a related donor will lead to the reduction of aGVHD and TRM.
The median age of 44 years old of the patients in this series is apparently less than that of general ATLL patients (about 60 years old in Japan). Although there was some bias in case selection, our results demonstrated that allo-HSCT can provide apparent long-term RFS in some patients, the GvATLL effect was actually observed. In a patient who was transplanted from a seronegative donor, the original ATLL population in peripheral blood was not detected by Southern blot analysis 6 years after transplantation. However, anti-HTLV-I antibody was positive (data not shown). It is necessary to analyze the precise virological status of recipients after allo-HSCT using techniques such as PCR to understand how it works on ATLL. Further prospective controlled studies are needed to assess the efficacy of allo-HSCT for ATLL and the GvATLL effect. Sustained long-term survival of patients with ATLL after allo-HSCT T Fukushima et al
